

Myceliophthora, *Myrothecium*, *Neocallimastix*, *Neurospora*, *Paecilomyces*, *Penicillium*, *Piromyces*, *Schizophyllum*, *Talaromyces*, *Thermoascus*, *Thielavia*, *Tolypocladium*, or *Trichoderma* cell.

72. The method of claim 70, wherein the filamentous fungal cell is a *Fusarium* cell.
73. The method of claim 72, wherein the *Fusarium* cell is a *Fusarium venenatum* cell.
74. The method of claim 73, wherein the *Fusarium venenatum* cell is *Fusarium venenatum* ATCC 20334.
75. The method of claim 73, wherein the *Fusarium venenatum* cell is a morphological mutant.
76. The method of claim 75, wherein the *Fusarium venenatum* cell is a morphological mutant of *Fusarium venenatum* ATCC 20334.
77. The method of claim 70, wherein the mutant cell comprises a second nucleic acid sequence which comprises a modification of at least one of the genes involved in the production of the cyclohexadepsipeptide.
78. The method of claim 77, wherein the genes are selected from the group consisting of a cyclohexadepsipeptide synthetase gene, enniatin synthetase gene, and D-hydroxyisovalerate dehydrogenase gene.
79. The method of claim 77, wherein one of the genes is a cyclohexadepsipeptide synthetase gene.
80. The method of claim 77, wherein one of the genes is an enniatin synthetase gene.
81. The method of claim 77, wherein one of the genes is a D-hydroxyisovalerate dehydrogenase gene.
82. The method of claim 70, wherein the mutant cell produces at least about 25% less of the cyclohexadepsipeptide than the parent filamentous fungal cell when cultured under identical

conditions.

83. The method of claim 70, wherein the mutant cell produces no cyclohexadepsipeptide.
84. The method of claim 70, wherein the filamentous fungal cell comprises at least two copies of the first nucleic acid sequence.
85. The method of claim 70, wherein the secreted heterologous polypeptide is a hormone, enzyme, receptor or portion thereof, antibody or portion thereof, or reporter.
86. The method of claim 85, wherein the enzyme is an oxidoreductase, transferase, hydrolase, lyase, isomerase, or ligase.
87. The method of claim 86, wherein the enzyme is an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, a pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, or xylanase.
88. The method of claim 70, wherein the mutant cell further comprises one or more modifications of one or more third nucleic acid sequences, wherein the modification reduces or eliminates expression of the one or more third nucleic acid sequences.
89. The method of claim 88, wherein the third nucleic acid sequence encodes an enzyme selected from the group consisting of an aminopeptidase, amylase, carbohydrase, carboxypeptidase, catalase, cellulase, chitinase, cutinase, cyclodextrin glycosyltransferase, deoxyribonuclease, esterase, alpha-galactosidase, beta-galactosidase, glucoamylase, alpha-glucosidase, beta-glucosidase, invertase, laccase, lipase, mannosidase, mutanase, oxidase, pectinolytic enzyme, peroxidase, phytase, polyphenoloxidase, proteolytic enzyme, ribonuclease, transglutaminase, and xylanase.
90. The method of claim 88, wherein the third nucleic acid sequence encodes a protease.

91. A cyclohexadepsipeptide-deficient mutant cell of a parent filamentous fungal cell, comprising a first nucleic acid sequence encoding a secreted heterologous polypeptide, wherein the mutant cell produces less of a cyclohexadepsipeptide than the parent filamentous fungal cell of the mutant cell when cultured under the same conditions.

92. The mutant cell of claim 91, wherein the mutant cell comprises a second nucleic acid sequence which comprises a modification of at least one of the genes involved in the production of the cyclohexadepsipeptide.

93. The mutant cell of claim 92, wherein the genes are selected from the group consisting of a cyclohexadepsipeptide synthetase gene, enniatin synthetase gene, and D-hydroxyisovalerate dehydrogenase gene.

94. The mutant cell of claim 92, wherein one of the genes is a cyclohexadepsipeptide synthetase gene.

95. The mutant cell of claim 92, wherein one of the genes is an enniatin synthetase gene.

96. The mutant cell of claim 92, wherein one of the genes is a D-hydroxyisovalerate dehydrogenase gene.

97. The mutant cell of claim 91, wherein the cell comprises at least two copies of the first nucleic acid sequence.

REMARKS

Claims 1-3, 8, 9, 13, 22-24, 30, 31, 37, 42, 50, 53, 57-59, 63, and 64 have been canceled. New claims 70-97 have been added and are pending in the present application.

It is respectfully submitted that the present amendment presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above amendments and the following remarks is requested.

I. The Rejection of Claim 8 under 35 U.S.C. § 112, Second Paragraph

Claims 8 stands rejected under 35 U.S.C. § 112, second paragraph, as being indefinite